Form 4 for RMD ResMed|
Accepted 2025-05-09 00:00:00 ET · period of report 2025-05-07 · accession 0001127602-25-013796 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-05-09 | 2025-05-07 | RMD | Farrell Michael J. | CEO | S - Sale+OE | $243.23 | -8,009 | 455.5K | -2% | -$1.95M |
| D | 2025-05-09 | 2025-05-07 | RMD | Farrell Michael J. | CEO | M - OptEx | $101.64 | +8,009 | 463.5K | +2% | +$814.0K |
| D | 2025-05-09 | 2025-05-07 | RMD | Farrell Michael J. | CEO | M - OptEx | $0.00 | -8,009 | 48.1K | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | ResMed Common Stock | 2025-05-07 | S | D | 8,009 | $243.23 | 455,503 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $241.50 - $245.09. The price reported above reflects the weighted average sale price. |
| 2 | Common | ResMed Common Stock | 2025-05-07 | M | A | 8,009 | $101.64 | 463,512 | D | — | — | (F2) Includes 30.3711 shares of ResMed stock purchased on April 30, 2025, through the ResMed Employee Stock Purchase Plan. |
| 3 | Derivative | ResMed Common Stock Options | 2025-05-07 | M | D | 8,009 | $0.00 | 48,056 | D | $101.64 · 2019-11-11 to 2025-11-14 | 8,009 ResMed Common Stock | (F4) Represents date options first become exercisable. Options vest 1/3 per year. |